SLI
2.093,82
PKT
+2,06
PKT
+0,10
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 20.01.05 | Swiss Life Halten | Bankhaus Lampe | |
| 17.01.05 | Swiss Life Buy | M.M. Warburg | |
| 14.01.05 | Geberit Buy | Sarasin Research | |
| 14.01.05 | Novartis Overweight | Lehman Brothers | |
| 18.01.05 | UBS Empfehlungsliste | Erste Bank | |
| 14.01.05 | Novartis Kaufen | Helaba Trust | |
| 18.01.05 | Novartis Empfehlungsliste | Erste Bank | |
| 13.01.05 | Holcim In-Line | Goldman Sachs | |
| 14.01.05 | UBS Kaufen | Hamburger Sparkasse | |
| 18.01.05 | Straumann Outperform | Credit Suisse First Boston | |
| 13.01.05 | Logitech Market Perform | Vontobel | |
| 14.01.05 | ABB (Asea Brown Boveri) Halten | Hamburger Sparkasse | |
| 17.01.05 | Sonova Outperform | Credit Suisse First Boston | |
| 13.01.05 | Novartis Buy | AG Edwards | |
| 12.01.05 | Novartis Hold | Smith Barney Citigroup | |
| 13.01.05 | Holcim Buy | Dresdner Kleinwort Wasserstein | |
| 13.01.05 | Geberit Buy | Sarasin Research | |
| 14.01.05 | Temenos Market Outperform | Vontobel | |
| 13.01.05 | Novartis Kaufen | Hamburger Sparkasse | |
| 13.01.05 | Holcim Halten | Helaba Trust | |
| 13.01.05 | Richemont Kaufen | Hamburger Sparkasse | |
| 11.01.05 | Novartis Sell | Banc of America Sec. | |
| 11.01.05 | Adecco SA Buy | UBS | |
| 12.01.05 | UBS Kaufen | Conrad Hinrich Donner | |
| 10.01.05 | Lonza Underperform | Goldman Sachs | |
| 11.01.05 | UBS Empfehlungsliste | Erste Bank | |
| 07.01.05 | SGS SA Neutral | Sarasin Research | |
| 11.01.05 | Novartis Empfehlungsliste | Erste Bank | |
| 05.01.05 | Holcim Akkumulieren | Independent Research | |
| 05.01.05 | Nestlé Neutral | Sarasin Research | |
| 04.01.05 | Novartis Buy | Deutsche Securities | |
| 03.01.05 | Swatch (I) Buy | Sarasin Research | |
| 03.01.05 | Holcim Halten | Helaba Trust | |
| 12.01.05 | UBS Market Perform | Vontobel | |
| 12.01.05 | UBS Market Outperform | Vontobel | |
| 09.02.05 | UBS Buy | Sarasin Research | |
| 28.01.05 | Holcim Overweight | JP Morgan | |
| 18.01.05 | Novartis Outperform | Goldman Sachs |